Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-02-15
1996-10-01
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A61K 31495
Patent
active
055611320
ABSTRACT:
A method of treating a mammal comprising administering an effective amount of a compound of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, is disclosed wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms wherein the desired therapeutic effect is an alteration in the rate of fluid transport in the gastrointestinal tract.
REFERENCES:
patent: 3890319 (1975-06-01), Danielewicz et al.
patent: 4188393 (1980-02-01), Neumann
patent: 4656291 (1987-04-01), Maryanoff et al.
patent: 5021416 (1991-06-01), Gluchowski
patent: 5034406 (1991-07-01), Gluchowski
patent: 5077292 (1991-12-01), Gluchowski
patent: 5112822 (1992-05-01), Gluchowski
patent: 5130441 (1992-07-01), Gluchowski
patent: 5198442 (1993-03-01), Gluchowski
patent: 5204347 (1993-04-01), Gluchowski
patent: 5231096 (1993-07-01), Gluchowski
patent: 5237072 (1993-08-01), Gluchowski
Hamilton, C., Pharmac. Ther. vol. 54 (3) (1992), pp. 231-248.
P. Thaina et al., Journal of Autonomic Pharm., vol. 13, No. 2, pp. 95-176, Apr. 1993.
Bradley et al., Neuropharmacology, vol. 25, No. 4, Apr. 1986, pp. 391-396.
BR J Pharmacology (England), Jun. 1986, vol. 88, No. 2 pp. 345-354, Berridge TL et al., "Characterization of alpha-adrenoceptors in the vasculature of the canine nasal mucosa."
Gastroenterology, 1984, vol. 86, pp. 120-128, Dharmsathaphorn, Diertisin et al. "Effects of structure-activity relationships of alpha-a energic compounds on electrolyte transport in the rabbit ileum and rat colon".
Gellai et al., J. Pharm. & Exp. Therapeutics, 240(3), pp. 723-728, 1986.
Gellai et al., Mechanism of Alpha-2-Adrenoceptor Agonist-induced Diuresis, 1988, Am. Physio. Soc., F317-F323.
Chemical Abstracts CA105:48lu, vol. 105, 1986.
Hieble, et al., A Potent Peripherally Acting, Alpha-Adrenoce Agonist, The Pharmologist, 1991, vol. 33, #3, pp. 214.
C. F. Colpaert, Maximal Magnitude of Effect & Potency of Putative Alpha-Adrenoceptor Agonists in Causing CNS Depression, in Relaxing Muscle, and in Lowering Body Temp. in Rat, Drug Dev. Research, 7:209-220 (1986).
Alpha 2-adrenoceptor antisecretory responses in the rat jejunum (published erratum appears in J Auton Pharmacol 1990 Aug.; 10(4):247), Williams et al.
Norepinephrine and alpha-2 adrenoceptors molulate active ion transport in porcine small intestine, J. Pharmacol Exp Ther, Nov. 1992, 263(2) p. 510-9.
Fondacaro et al., J. Pharm. & Exp. Therap. 247 (2) 1988, 481-486.
Ekas et al, Increased presynaptic alpha-adrenoceptor mediated regulation of spontaneously hypertensive rats, Chemical Abstracts, vol. 98, No. 1, Jan. 3, 1983, p. 918.
De Mey et al., Differences in pharmacological properties of postjunctional alpha-adrenergic receptors among arteries and veins, Chemical Abstracts, vol. 93, No. 13, Sept. 29, 1980, p. 96.
Walland, Inhibition of a somato-sympathetic reflex via peripheral presynaptic alpha-adrenoceptors, Chemical Abstracts, vol. 88, No. 23, Jun. 5, 1978, p. 80.
Philippu et al., Changes in the arterial blood pressure increase the release of endogenous histamine in the hypothalamus of anesthetized cats, Chemical Abstracts, vol. 99, No. 15, Oct. 10, 1983, p. 137.
Ekas et al., Presynaptic alpha-and beta-adrenoceptor stimulation andnorepinephrine release in the spontaneously hypertensive rat, Chemical Abstracts, vol. 98, No. 25, p. 109 (1983).
Steppler et al., Pre- and postsynaptic effects of phenylephrine and tramazoline on blood vessels in vivo, Chem. Abstracts, vol. 91, No. 21, Nov. 19, 1979, p. 43.
Steppeler et al., A comparison of pre- and postsynaptic alpha-adrenergic effects of phenylephrine and tramazoline on blood vessels of the rabbit in vivo, Chem. Abstracts, vol. 90, No. 5, Jan. 29, 1979, p. 37.
Timmermans et al., Hypotensive and bradycardic effects of classical alpha-sympathomimetic drugs upon intravenous administration to pentobarbiton-anesthetized rate, Chem. Abstract, vol. 89, No. 1, Jul. 3, 1978. p. 49.
Boudier et al., Central and peripheral alpha adrenergic activity of imidazoline derivatives, Chemical Abstract, vol. 82, No. 17, Apr. 28, 1975, p. 13.
Burke et al., Current Eye Research; Sept. 5(9): 665-76 1986.
Mittag. Annals of Ophthalmology 1983; 15(3): 201-202.
Fielding, "Clonidine:New Research in Psychotropic Drug Pharmacology", Medicinal Research Reviews, vol. 1, No. 1 pp. 97-123 (1981).
Isom et al., "a2-Adrenergic Receptors Accelerate Na /H Exchange in Neuroblastoma X Glioma Cells", The Journal of Biological Chemistry vol. 262, No. 14, Issue of May 15, 1987, pp. 6750-6757.
Pieter, et al., "Clonidine and Some Bridge Analogues; Cardiovascular Effects and Nuclear Magnetic Resonance Data(.sup.1 H/.sup.13)", Fur. J. Med. Chem, Jul.-Aug. 1980, vol. 4, pp. 323-329.
Langer et al., "Pharmacologic and Therapeutic Significance of a Adrenoceptor Subtypes", Journal of Cardiovascular Pharmacology, vol. 7, Supp. 8(S1-S8) 1988.
Nielsen et al., "Postjunctional a.sub.2 ]adrenoceptors mediate vasoconstrict in human subcutaneous resistance vessels", Br. J. Pharmacol (1989), 97 (829-834).
B. Bloor, "Clonidine and Other Alpha.sub.2 Adrenergic Agonists; An Important New Drug Class for the Perioperative Period", Seminars in Anesthesia, vol. VII, No. 3(Sep.), 1988: (pp. 170-177).
Sato et al., "Adrenergic Excitation of Cutaneous Pain Receptors Induced by Peripheral Nerve Injury", Science, vol. 251, (Mar., 1991), (pp. 1608-1610).
Jarrot, "Clonidine and Related Compounds", Hardbook of Hypertension, vol. 5 (1980).
Bloor et al, "Reduction in Halothane Anesthetic Requirement by Clonidine, an Alpha-Adrenergic Agonist", Anesthesia & Analgesia, vol. 61, No. 9, Sep. 1982 (741-745).
Van Zwieten et al., "Central & Periphera a-Adrenoceptors, Pharmacological Aspects & Clinical Potential", Advances in Drug Research vol. 13, 1984 (209-254).
a2-Adrenergic Agonists: A Newer Class of Antidiarrheal Drug Gastroenterology 1986, vol. 91, pp. 769-775.
Mittag, Ocular Effects of Selective Alpha Adrenergic Agents: A New Drug Paradox?, Annals of Ophthalmology Mar. 1983.
Jumblatt et al., "Alpha-2 Adrenergic Modulation of Norepinephrine Secretion in the Perfused Rabbit Iris-Ciliary Body", Current Eye Research, 1987, vol. 6, pp. 767-777.
Burke et al., "Ocular Effects of a Relatively Selective a2 Agonist (UK-14, 304-18) in cats, rabbits and monkeys", Current Eye Research, 1986, vol. 5, pp. 665-676.
Fondacaro et al., "Selective Alpha-2 Adrenoceptor Agonists Alter Fluid and Electrolyte Transport in Mammalian Small Intestine" American Society for Pharmacology, vol. 247, 1987.
Bendele, et al., "Anti-Inflammatory Activity of Pergolide in Rats", Pharmacol (Aug.) 1991, (pp. 152), 82.
Scrip Product Information, Scrip No. 1466 Nov. 22, 1989(p. 28).
The Pharmacological Basis of Therapeutics, Gilman & Goodmen, 1985, "Therapeutic Uses of Sympathomimetic Drugs", (pp. 174-179), 7th Edition Chapter 8.
Cantiello et al., J. Biol. Chem. 264(27) pp. 16000-16007. 1989.
Burke James A.
Garst Michael E.
Wheeler Larry A.
Allergan
Spivack Phyllis G.
Uxa Frank J.
LandOfFree
Methods for using (2-imidazolin-2-ylamino) quinoxaline derivativ does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for using (2-imidazolin-2-ylamino) quinoxaline derivativ, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using (2-imidazolin-2-ylamino) quinoxaline derivativ will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1502119